Clinical Trials - April 22, 2026
Hemispherian initiates Phase 1/2a clinical trial
The company has announced the initiation of a first-in-human Phase 1/2a clinical trial of GLIX1 in patients with recurrent and progressive glioblastoma (GBM) and other high-grade gliomas.
Clinical Trials - April 22, 2026
Lytix Biopharma announces Phase II results
The company has announced final efficacy and safety results from its Phase II ATLAS-IT-05 study evaluating intratumoral ruxotemitide (LTX-315) in combination with pembrolizumab in patients with advanced melanoma who have progressed following prior checkpoint inhibitor therapy.
Clinical Trials - April 21, 2026
Novo Nordisk’s etavopivat met both co-primary endpoints in phase 3 trial
The company has announced the topline results from HIBISCUS, a phase 3 trial of once-daily oral etavopivat in adults and adolescents with sickle cell disease (SCD).
Clinical Trials - April 19, 2026
Evaxion’s AI-Immunology platform demonstrates 86% vaccine target precision
Evaxion has announced new data demonstrating that AI-Immunology identifies and selects the most therapeutically relevant vaccine targets.
Clinical Trials - April 15, 2026
Promising results about new Lyme disease vaccine candidate
Pfizer and Valneva's Lyme disease vaccine candidate demonstrated strong efficacy in their Phase 3 VALOR trial.
Clinical Trials - April 13, 2026
Mendus starts clinical program in chronic myeloid leukemia
The company has completed preparations and received all regulatory approvals for the VITAL-CML trial.
